OM:IMMNOV

Stock Analysis Report

Executive Summary

Immunovia AB (publ), a molecular diagnostics company, develops and commercializes diagnostic tools for cancer and autoimmune diseases in Sweden and internationally.


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Immunovia's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IMMNOV's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.6%

IMMNOV

3.0%

SE Medical Equipment

4.0%

SE Market


1 Year Return

-25.2%

IMMNOV

15.8%

SE Medical Equipment

-6.4%

SE Market

Return vs Industry: IMMNOV underperformed the Swedish Medical Equipment industry which returned 15.8% over the past year.

Return vs Market: IMMNOV underperformed the Swedish Market which returned -6.4% over the past year.


Shareholder returns

IMMNOVIndustryMarket
7 Day1.6%3.0%4.0%
30 Day-5.0%0.2%-8.3%
90 Day-22.2%-9.2%-17.8%
1 Year-25.2%-25.2%17.7%15.8%-4.4%-6.4%
3 Year19.9%19.9%37.7%22.0%6.8%-8.3%
5 Yearn/a25.7%3.7%13.7%-9.9%

Price Volatility Vs. Market

How volatile is Immunovia's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Immunovia undervalued compared to its fair value and its price relative to the market?

7.04x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IMMNOV's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IMMNOV's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IMMNOV is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: IMMNOV is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IMMNOV's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IMMNOV is overvalued based on its PB Ratio (7x) compared to the SE Medical Equipment industry average (3.9x).


Next Steps

Future Growth

How is Immunovia forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

24.2%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Immunovia has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Immunovia performed over the past 5 years?

-53.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IMMNOV is currently unprofitable.

Growing Profit Margin: IMMNOV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IMMNOV is unprofitable, and losses have increased over the past 5 years at a rate of -53.8% per year.

Accelerating Growth: Unable to compare IMMNOV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMMNOV is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.6%).


Return on Equity

High ROE: IMMNOV has a negative Return on Equity (-32.02%), as it is currently unprofitable.


Next Steps

Financial Health

How is Immunovia's financial position?


Financial Position Analysis

Short Term Liabilities: IMMNOV's short term assets (SEK269.2M) exceed its short term liabilities (SEK28.6M).

Long Term Liabilities: IMMNOV's short term assets (SEK269.2M) exceed its long term liabilities (SEK33.1M).


Debt to Equity History and Analysis

Debt Level: IMMNOV is debt free.

Reducing Debt: IMMNOV has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMMNOV has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IMMNOV has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of -40.8% each year.


Next Steps

Dividend

What is Immunovia's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IMMNOV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IMMNOV's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IMMNOV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IMMNOV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IMMNOV's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average management tenure


CEO

Mats Grahn (57yo)

7.25s

Tenure

kr3,680,000

Compensation

Mr. Mats Grahn has been Chief Executive Officer of Immunovia AB (publ) since 2013. Mr. Grahn served as the Vice President of Product Management of Protein Separations at GE Healthcare Ltd. He has more than ...


CEO Compensation Analysis

Compensation vs Market: Mats's total compensation ($USD363.46K) is about average for companies of similar size in the Swedish market ($USD468.25K).

Compensation vs Earnings: Mats's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Mats Grahn
Chief Executive Officer7.25yrskr3.68m1.86% SEK46.7m
Hans Liljenborg
Chief Financial Officer7.25yrsno data0.089% SEK2.2m
Lotta Blomgren
Operations Director3.58yrsno data0.053% SEK1.3m
Peter Schulz-Knappe
Chief Technology Officer0.33yrno datano data
Rolf Ehrnström
Chief Scientific Officer7.25yrsno data0.26% SEK6.5m
Julie Silber
Director of Investor Relationsno datano datano data
Laura Chirica
Chief Commercial Officer5.25yrsno data0.16% SEK4.1m
Henrik Winther
Senior Vice President of Business Development2.92yrsno datano data
Michael Pettigrew
Senior Vice President of Sales - North America0.25yrno datano data
Linda Mellby
Vice President of Research & Development6.25yrsno data0.17% SEK4.2m

5.3yrs

Average Tenure

57yo

Average Age

Experienced Management: IMMNOV's management team is seasoned and experienced (5.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Carl Arne Borrebäck
Chairman of the Board of Directors13.25yrskr420.00k8.7% SEK218.9m
Hans Johansson
Director3.25yrskr170.00k0.15% SEK3.7m
Margaret Tempero
Member of Scientific Advisory Board3.83yrsno datano data
Ann-Christine Sundell
Director3.25yrskr190.00kno data
Christofer Sjögren
Director2.25yrskr177.00k0.19% SEK4.8m
Diane Simeone
Member of Scientific Advisory Board3.75yrsno datano data
Marco Del Chiaro
Member of Advisory Board4yrsno datano data
Aldo Scarpa
Member of Scientific Advisory Board3.75yrsno datano data
Stephen Pereira
Member of Scientific Advisory Board2.75yrsno datano data
Mimmi Ekberg
Director2.25yrskr150.00kno data

3.5yrs

Average Tenure

60yo

Average Age

Experienced Board: IMMNOV's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: IMMNOV insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.5%.


Top Shareholders

Company Information

Immunovia AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Immunovia AB (publ)
  • Ticker: IMMNOV
  • Exchange: OM
  • Founded: 2007
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr2.516b
  • Shares outstanding: 19.65m
  • Website: https://www.immunovia.com

Number of Employees


Location

  • Immunovia AB (publ)
  • Medicon Village
  • Scheelevägen 2
  • Lund
  • Skåne County
  • 223 81
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IMMNOVOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKDec 2015
0G8XLSE (London Stock Exchange)YesShare CapitalGBSEKDec 2015
IMMV.FOTCPK (Pink Sheets LLC)YesShare CapitalUSUSDDec 2015
IMMNOSBATS-CHIXE (BATS 'Chi-X Europe')YesShare CapitalGBSEKDec 2015

Biography

Immunovia AB (publ), a molecular diagnostics company, develops and commercializes diagnostic tools for cancer and autoimmune diseases in Sweden and internationally. The company offers IMMray PanCan-d, a blood-based test for the detection of pancreatic cancer. Immunovia AB (publ) was founded in 2007 and is headquartered in Lund, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/08 03:04
End of Day Share Price2020/04/07 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.